Parabilis Medicines, Inc. PBLS
29.25 USD +2.00 (+7.34%)
At closeNov 4, 2026, 8:09 AM EST
28.80 -0.45 -1.54%
Pre-market · Nov 4, 8:09 AM ET
27.90 Day range 29.73
22.66 52-week range 42.49
- YTD
- -7.44%
- 1 year
- -7.44%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 41.40 +41.5% upside
Now 29.25
- Target (low)
- 40.00
- Target (mean)
- 41.40
- Target (high)
- 45.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy0
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.38 | -0.45 – -0.25 | 0.00 | 0.0% | 500.00K | 0.0% | 3 |
| Next quarter | -0.39667 | -0.47 – -0.26 | 0.00 | 0.0% | 1.00M | 0.0% | 3 |
| Current year | -2.58 | -3.09 – -1.63 | 0.00 | 0.0% | 1.19M | 0.0% | 3 |
| Next year | -2.19 | -3.37 – -1.19 | -2.58 | +15.1% | 4.75M | +300.2% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Jul 6, 2026 | Guggenheim | Initiated | — | Buy |
| Jul 6, 2026 | Leerink Partners | Initiated | — | Outperform |
| Jul 6, 2026 | B of A Securities | Initiated | — | Buy |